The CD39-adenosinergic axis in the pathogenesis of renal ischemia-reperfusion injury

Purinergic Signalling

Volumn 9, Issue 2, 2013, Pages 135-143

  Roberts, Veena ^a   Lu, Bo ^a   Rajakumar, Siddharth ^a   Cowan, Peter J ^a   Dwyer, Karen M ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

Adenosine receptor; Ectonucleotidase; Ischemia reperfusion injury; Purinergic signalling; Renal transplant

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE RECEPTOR; CD39 ANTIGEN; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GAMMA INTERFERON; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; PROGRAMMED DEATH 1 LIGAND 1; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE KINASE 1; TUMOR NECROSIS FACTOR ALPHA;

CD4+ T LYMPHOCYTE; HUMAN; ISCHEMIC PRECONDITIONING; KIDNEY INJURY; META ANALYSIS (TOPIC); NONHUMAN; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

ADENOSINE; ANIMALS; ANTIGENS, CD; APYRASE; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

EID: 84877628063     PISSN: 15739538     EISSN: 15739546     Source Type: Journal    
DOI: 10.1007/s11302-012-9342-3     Document Type: Review

References (102)

1. Lohman AW, Billaud M, Isakson BE (2012) Mechanisms of ATP release and signalling in the blood vessel wall. Cardiovasc Res 95(3): 269-280.
2. Burnstock G (2007) Purine and pyrimidine receptors. Cell Mol Life Sci 64(12): 1471-1483.
3. Peng W, Cotrina ML, Han X, Yu H, Bekar L, Blum L et al (2009) Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury. Proc Natl Acad Sci USA 106(30): 12489-12493.
4. Riegel A-K, Faigle M, Zug S, Rosenberger P, Robaye B, Boeynaems J-M et al (2011) Selective induction of endothelial P2Y6 nucleotide receptor promotes vascular inflammation. Blood 117(8): 2548-2555.
5. McDonald B, Pittman K, Menezes GB, Hirota SA, Slaba I, Waterhouse CC et al (2010) Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 330(6002): 362-366.
6. Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A et al (2006) ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 314(5806): 1792-1795.
7. Robson SC, Sevigny J, Zimmermann H (2006) The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purinergic Signal 2(2): 409-430.
8. Kishore BK, Isaac J, Fausther M, Tripp SR, Shi H, Gill PS et al (2005) Expression of NTPDase1 and NTPDase2 in murine kidney: relevance to regulation of P2 receptor signaling. Am J Physiol Renal Physiol 288(5): F1032-F1043.
9. Stefan C, Jansen S, Bollen M (2006) Modulation of purinergic signaling by NPP-type ectophosphodiesterases. Purinergic signal 2(2): 361-370.
10. Goding JW, Grobben B, Slegers H (2003) Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/phosphodiesterase family. Biochim Biophys Acta Mol Basis Dis 1638(1): 1-19.
11. Yap SC, Lee HT (2012) Adenosine and protection from acute kidney injury. Curr Opin Nephrol Hypertens 21(1): 24-32.
12. Eltzschig HK, Carmeliet P (2011) Hypoxia and inflammation. N Engl J Med 364(7): 656-665.
13. Downey JM, Liu GS, Thornton JD (1993) Adenosine and the anti-infarct effects of preconditioning. Cardiovasc Res 27(1): 3-8.
14. Bauerle JD, Grenz A, Kim JH, Lee HT, Eltzschig HK (2011) Adenosine generation and signaling during acute kidney injury. J Am Soc Nephrol 22(1): 14-20.
15. Lee HT, Emala CW (2000) Protective effects of renal ischemic preconditioning and adenosine pretreatment: role of A(1) and A(3) receptors. Am J Physiol Renal Physiol 278(3): F380-F387.
16. Lee HT, Gallos G, Nasr SH, Emala CW (2004) A1 adenosine receptor activation inhibits inflammation, necrosis, and apoptosis after renal ischemia-reperfusion injury in mice. J Am Soc Nephrol 15(1): 102-111.
17. Lee HT, Xu H, Nasr SH, Schnermann J, Emala CW (2004) A1 adenosine receptor knockout mice exhibit increased renal injury following ischemia and reperfusion. Am J Physiol Renal Physiol 286(2): F298-F306.
18. Park SW, Kim M, Kim JY, Brown KM, Haase VH, D'Agati VD, et al. (2012) Proximal tubule sphingosine kinase-1 has a critical role in A(1) adenosine receptor-mediated renal protection from ischemia. Kidney Int 82: 878-891 (Jun 13).
19. Park SW, Kim JY, Ham A, Brown KM, Kim M, D'Agati VD, et al. (2012) A1 adenosine receptor allosteric enhancer PD-81723 protects against renal ischemia reperfusion injury. Am J Physiol Renal Physiol. Jul 3.
20. Gill A, Wortham K, Costa D, Davis W, Ticho B, Whalley E (2009) Protective effect of tonapofylline (BG9928), an adenosine A1 receptor antagonist, against cisplatin-induced acute kidney injury in rats. Am J Nephrol 30(6): 521-526.
21. Lee HT, Jan M, Bae SC, Joo JD, Goubaeva FR, Yang J et al (2006) A1 adenosine receptor knockout mice are protected against acute radiocontrast nephropathy in vivo. Am J Physiol Renal Physiol 290(6): F1367-F1375.
22. Hu S, Dong H, Zhang H, Wang S, Hou L, Chen S et al (2012) Noninvasive limb remote ischemic preconditioning contributes neuroprotective effects via activation of adenosine A1 receptor and redox status after transient focal cerebral ischemia in rats. Brain Res 1459: 81-90.
23. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A et al (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204(6): 1257-1265.
24. Sitkovsky M, Lukashev D, Deaglio S, Dwyer K, Robson SC, Ohta A (2008) Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br J Pharmacol 153(Suppl 1): S457-S464.
25. Day YJ, Huang L, Ye H, Li L, Linden J, Okusa MD (2006) Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: the role of CD4+ T cells and IFN-gamma. J Immunol 176(5): 3108-3114.
26. Yang Z, Day YJ, Toufektsian MC, Ramos SI, Marshall M, Wang XQ et al (2005) Infarct-sparing effect of A2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation 111(17): 2190-2197.
27. Lappas CM, Day YJ, Marshall MA, Engelhard VH, Linden J (2006) Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med 203(12): 2639-2648.
28. Grenz A, Osswald H, Eckle T, Yang D, Zhang H, Tran ZV et al (2008) The reno-vascular A2B adenosine receptor protects the kidney from ischemia. PLoS Med 5(6): e137.
29. Grenz A, Bauerle JD, Dalton JH, Ridyard D, Badulak A, Tak E et al (2012) Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice. J Clin Invest 122(2): 693-710.
30. Chouker A, Ohta A, Martignoni A, Lukashev D, Zacharia LC, Jackson EK et al (2012) In vivo hypoxic preconditioning protects from warm liver ischemia-reperfusion injury through the adenosine A2B receptor. Transplantation 94(9): 894-902.
31. Kong T, Westerman KA, Faigle M, Eltzschig HK, Colgan SP (2006) HIF-dependent induction of adenosine A2B receptor in hypoxia. FASEB J 20(13): 2242-2250.
32. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK et al (2002) Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 110(7): 993-1002.
33. Eltzschig HK, Abdulla P, Hoffman E, Hamilton KE, Daniels D, Schonfeld C et al (2005) HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J Exp Med 202(11): 1493-1505.
34. Hart ML, Grenz A, Gorzolla IC, Schittenhelm J, Dalton JH, Eltzschig HK (2011) Hypoxia-inducible factor-1alpha-dependent protection from intestinal ischemia/reperfusion injury involves ecto-5′-nucleotidase (CD73) and the A2B adenosine receptor. J Immunol 186(7): 4367-4374.
35. Yang M, Ma C, Liu S, Shao Q, Gao W, Song B et al (2010) HIF-dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2-stimulating phenotype under hypoxia. Immunol Cell Biol 88(2): 165-171.
36. Eckle T, Krahn T, Grenz A, Kohler D, Mittelbronn M, Ledent C et al (2007) Cardioprotection by ecto-5′-nucleotidase (CD73) and A2B adenosine receptors. Circulation 115(12): 1581-1590.
37. Eckle T, Hartmann K, Bonney S, Reithel S, Mittelbronn M, Walker LA et al (2012) Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia. Nat Med 18(5): 774-782.
38. Koeppen M, Harter PN, Bonney S, Bonney M, Reithel S, Zachskorn C et al (2012) Adora2b signaling on bone marrow derived cells dampens myocardial ischemia-reperfusion injury. Anesthesiology 116(6): 1245-1257.
39. Methner C, Schmidt K, Cohen MV, Downey JM, Krieg T (2010) Both A2a and A2b adenosine receptors at reperfusion are necessary to reduce infarct size in mouse hearts. Am J Physiol Heart Circ Physiol 299(4): H1262-H1264.
40. Vallon V, Muhlbauer B, Osswald H (2006) Adenosine and kidney function. Physiol Rev 86(3): 901-940.
41. Lee HT, Ota-Setlik A, Xu H, D'Agati VD, Jacobson MA, Emala CW (2003) A3 adenosine receptor knockout mice are protected against ischemia- and myoglobinuria-induced renal failure. Am J Physiol Renal Physiol 284(2): F267-F273.
42. Crikis S, Lu B, Murray-Segal LM, Selan C, Robson SC, D'Apice AJ et al (2010) Transgenic overexpression of CD39 protects against renal ischemia-reperfusion and transplant vascular injury. Am J Transplant 10(12): 2586-2595.
43. Lu B, Rajakumar SV, Robson SC, Lee EK, Crikis S, d'Apice AJ et al (2008) The impact of purinergic signaling on renal ischemia-reperfusion injury. Transplantation 86(12): 1707-1712.
44. Sun X, Imai M, Nowak-Machen M, Guckelberger O, Enjyoji K, Wu Y et al (2011) Liver damage and systemic inflammatory responses are exacerbated by the genetic deletion of CD39 in total hepatic ischemia. Purinergic Signal 7(4): 427-434.
45. Eltzschig HK, Köhler D, Eckle T, Kong T, Robson SC, Colgan SP (2009) Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. Blood 113(1): 224-232.
46. Guckelberger O, Sun XF, Sévigny J, Imai M, Kaczmarek E, Enjyoji K et al (2004) Beneficial effects of CD39/ecto-nucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion injury. Thrombo Haemo 91(3): 576-586.
47. Grenz A, Zhang H, Hermes M, Eckle T, Klingel K, Huang DY et al (2007) Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury. FASEB J 21(11): 2863-2873.
48. Hart ML, Gorzolla IC, Schittenhelm J, Robson SC, Eltzschig HK (2010) SP1-dependent induction of CD39 facilitates hepatic ischemic preconditioning. J Immunol 184(7): 4017-4024.
49. Dwyer KM, Robson SC, Nandurkar HH, Campbell DJ, Gock H, Murray-Segal LJ et al (2004) Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest 113(10): 1440-1446.
50. Rajakumar SV, Lu B, Crikis S, Robson SC, d'Apice AJF, Cowan PJ et al (2010) Deficiency or inhibition of CD73 protects in mild kidney ischemia-reperfusion injury. Transplantation 90(12): 1260-1264. doi: 10. 097/TP. 0b013e3182003d9b.
51. Cai M, Huttinger ZM, He H, Zhang W, Li F, Goodman LA et al (2011) Transgenic over expression of ectonucleotide triphosphate diphosphohydrolase-1 protects against murine myocardial ischemic injury. J Mol Cell Cardiol 51(6): 927-935.
52. Wheeler DG, Joseph ME, Mahamud SD, Aurand WL, Mohler PJ, Pompili VJ et al (2012) Transgenic swine: expression of human CD39 protects against myocardial injury. J Mol Cell Cardiol 52(5): 958-961.
53. Pommey S, Lu B, McRae J, Stagg J, Hill P, Salvaris E, et al. (2012) Liver grafts from CD39-overexpressing mice are protected from ischemia reperfusion injury due to reduced numbers of resident CD4(+) T cells. Hepatology Jul 24. doi: 10. 1002/hep. 25985.
54. Banz Y, Beldi G, Wu Y, Atkinson B, Usheva A, Robson SC (2008) CD39 is incorporated into plasma microparticles where it maintains functional properties and impacts endothelial activation. Br J Haematol 142(4): 627-637.
55. Cantaluppi V, Gatti S, Medica D, Figliolini F, Bruno S, Deregibus MC et al (2012) Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia-reperfusion injury by microRNA-dependent reprogramming of resident renal cells. Kidney Int 82(4): 412-427.
56. Thompson LF, Eltzschig HK, Ibla JC, van De Wiele CJ, Resta R, Morote-Garcia JC et al (2004) Crucial role for ecto-5′-nucleotidase (CD73) in vascular leakage during hypoxia. J Exp Med 200(11): 1395-1405.
57. Zernecke A, Bidzhekov K, Ozuyaman B, Fraemohs L, Liehn EA, Luscher-Firzlaff JM et al (2006) CD73/ecto-5′-nucleotidase protects against vascular inflammation and neointima formation. Circulation 113(17): 2120-2127.
58. Eckle T, Faigle M, Grenz A, Laucher S, Thompson LF, Eltzschig HK (2008) A2B adenosine receptor dampens hypoxia-induced vascular leak. Blood 111(4): 2024-2035.
59. Eltzschig HK, Thompson LF, Karhausen J, Cotta RJ, Ibla JC, Robson SC et al (2004) Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood 104(13): 3986-3992.
60. Lennon PF, Taylor CT, Stahl GL, Colgan SP (1998) Neutrophil-derived 5-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation. J Exp Med 188(8): 1433-1443.
61. Grenz A, Zhang H, Eckle T, Mittelbronn M, Wehrmann M, Köhle C et al (2007) Protective role of ecto-5′-nucleotidase (CD73) in renal ischemia. J Am Soc Nephrol 18(3): 833-845.
62. Hart ML, Much C, Grozolla IC, Schittenhelm J, Kloor D, Stahl GL et al (2008) Extracellular adenosine production by Ecto-5-nucleotidase protects during murine hepatic ischemic preconditioning. Gastroenterology 135: 1739-1750.
63. Narravula S, Lennon PF, Mueller BU, Colgan SP (2000) Regulation of endothelial CD73 by adenosine: paracrine pathway for enhanced endothelial barrier function. J Immunol 165(9): 5262-5268.
64. Kiss J, Yegutkin GG, Koskinen K, Savunen T, Jalkanen S, Salmi M (2007) IFN-beta protects from vascular leakage via up-regulation of CD73. Eur J Immunol 37(12): 3334-3338.
65. Jian R, Sun Y, Wang Y, Yu J, Zhong L, Zhou P (2012) CD73 protects kidney from ischemia-reperfusion injury through reduction of free radicals. APMIS 120(2): 130-138.
66. Rittiner JE, Korboukh I, Hull-Ryde EA, Jin J, Janzen WP, Frye SV et al (2012) The nucleotide AMP is an adenosine A1 receptor agonist. J Biol Chem 3: 2012.
67. Haller CA, Cui W, Wen J, Robson SC, Chaikof EL (2006) Reconstitution of CD39 in liposomes amplifies nucleoside triphosphate diphosphohydrolase activity and restores thromboregulatory properties. J Vasc Surg 43(4): 816-823.
68. Rabb H (2002) The T, cell as a bridge between innate and adaptive immune systems: implications for the kidney. Kidney Int 61(6): 1935-1946.
69. Burne-Taney MJ, Yokota-Ikeda N, Rabb H (2005) Effects of combined T- and B-cell deficiency on murine ischemia reperfusion injury. Am J Transplant 5(6): 1186-1193.
70. Yilmaz G, Arumugam TV, Stokes KY, Granger DN (2006) Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation 113(17): 2105-2112.
71. Burne MJ, Daniels F, El Ghandour A, Mauiyyedi S, Colvin RB, O'Donnell MP et al (2001) Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest 108(9): 1283-1290.
72. Yokota N, Burne-Taney M, Racusen L, Rabb H (2003) Contrasting roles for STAT4 and STAT6 signal transduction pathways in murine renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 285(2): F319-F325.
73. Shichita T, Sugiyama Y, Ooboshi H, Sugimori H, Nakagawa R, Takada I et al (2009) Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med 15(8): 946-950.
74. Bonner F, Borg N, Burghoff S, Schrader J (2012) Resident cardiac immune cells and expression of the ectonucleotidase enzymes CD39 and CD73 after ischemic injury. PLoS One 7(4): e34730.
75. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R et al (2007) Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110(4): 1225-1232.
76. Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR (2006) T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5′-adenosine monophosphate to adenosine. J Immunol 177(10): 6780-6786.
77. Kinsey GR, Huang L, Jaworska K, Khutsishvili K, Becker DA, Ye H, et al. (2012) Autocrine adenosine signaling promotes regulatory T cell-Mediated Renal Protection. J Am Soc Nephrol 23: 1528-1537 (Jul 26).
78. Kinsey GR, Sharma R, Huang L, Li L, Vergis AL, Ye H et al (2009) Regulatory T cells suppress innate immunity in kidney ischemia-reperfusion injury. J Am Soc Nephrol 20(8): 1744-1753.
79. Liesz A, Suri-Payer E, Veltkamp C, Doerr H, Sommer C, Rivest S et al (2009) Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med 15(2): 192-199.
80. Kinsey GR, Huang L, Vergis AL, Li L, Okusa MD (2010) Regulatory T cells contribute to the protective effect of ischemic preconditioning in the kidney. Kidney Int 77(9): 771-780.
81. Gandolfo MT, Jang HR, Bagnasco SM, Ko GJ, Agreda P, Satpute SR et al (2009) Foxp3+ regulatory T cells participate in repair of ischemic acute kidney injury. Kidney Int 76(7): 717-729.
82. Singh M, Shah T, Khosla K, Singh P, Molnar J, Khosla S et al (2012) Safety and efficacy of intracoronary adenosine administration in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of randomized controlled trials. Ther Adv Cardiovasc Dis 6(3): 101-114.
83. Mentzer RM Jr, Birjiniuk V, Khuri S, Lowe JE, Rahko PS, Weisel RD et al (1999) Adenosine myocardial protection: preliminary results of a phase II clinical trial. Ann Surg 229(5): 643-649, discussion 9-50.
84. Menasché P, Jamieson WRE, Flameng W, Michael KD (1995) Acadesine: a new drug that may improve myocardial protection in coronary artery bypass grafting: results of the first international multicenter study. J Thorac Cardiovasc Surg 110(4, Part 1): 1096-1106.
85. Matot I, Jurim O (2001) The protective effect of acadesine on lung ischemia-reperfusion injury. Anesth Analg 92(3): 590-595.
86. Mangano DT, Miao Y, Tudor IC, Dietzel C (2006) Post-reperfusion myocardial infarction: long-term survival improvement using adenosine regulation with acadesine. J Am Coll Cardiol 48(1): 206-214.
87. Mangano DT (1997) Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. The Multicenter Study of Perioperative Ischemia (McSPI) Research Group. JAMA 277(4): 325-332.
88. Newman MF, Ferguson TB, White JA, Ambrosio G, Koglin J, Nussmeier NA et al (2012) Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial. JAMA 308(2): 157-164.
89. George TJ, Arnaoutakis GJ, Beaty CA, Shah AS, Conte JV, Halushka MK (2012) A novel method of measuring cardiac preservation injury demonstrates University of Wisconsin solution is associated with less ischemic necrosis than Celsior in early cardiac allograft biopsy specimens. J Heart Lung Transpl 31(4): 410-418.
90. George TJ, Arnaoutakis GJ, Baumgartner WA, Shah AS, Conte JV (2011) Organ storage with University of Wisconsin solution is associated with improved outcomes after orthotopic heart transplantation. J Heart Lung Transpl 30(9): 1033-1043.
91. Hoeger S, Lueg G, Tsagogiorgas C, Schneider M, Theisinger S, Theisinger B et al (2011) UW is superior compared with HTK after prolonged preservation of renal grafts. J Surg Res 170(1): e149-e157.
92. Garcia-Gil FA, Serrano MT, Fuentes-Broto L, Arenas J, Garcia JJ, Guemes A et al (2011) Celsior versus University of Wisconsin preserving solutions for liver transplantation: postreperfusion syndrome and outcome of a 5-year prospective randomized controlled study. World J Surg 35(7): 1598-1607.
93. Rudd DM, Dobson GP (2011) Eight hours of cold static storage with adenosine and lidocaine (adenocaine) heart preservation solutions: toward therapeutic suspended animation. J Thorac Cardiovasc Surg 142(6): 1552-1561.
94. Rudd DM, Dobson GP (2011) Early reperfusion with warm, polarizing adenosine-lidocaine cardioplegia improves functional recovery after 6 hours of cold static storage. J Thorac Cardiovasc Surg 141(4): 1044-1055.
95. Veighey K, MacAllister RJ (2012) Clinical applications of remote ischemic preconditioning. Cardiol Res Pract 2012: 9.
96. Takaoka A, Nakae I, Mitsunami K, Yabe T, Morikawa S, Inubushi T et al (1999) Renal ischemia/reperfusion remotely improves myocardial energy metabolism during myocardial ischemia via adenosine receptors in rabbits: effects of "remote preconditioning". J Am Coll Cardiol 33(2): 556-564.
97. Liem DA, Verdouw PD, Ploeg H, Kazim S, Duncker DJ (2002) Sites of action of adenosine in interorgan preconditioning of the heart. Am J Physiol Heart Circ Physiol 283(1): H29-H37.
98. Philipp S, Yang X-M, Cui L, Davis AM, Downey JM, Cohen MV (2006) Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade. Cardiovasc Res 70(2): 308-314.
99. Er F, Nia AM, Dopp H, Hellmich M, Dahlem KM, Caglayan E et al (2012) Ischemic preconditioning for prevention of contrast medium-induced nephropathy/clinical perspective. Circulation 126(3): 296-303.
100. Ali ZA, Callaghan CJ, Lim E, Ali AA, Reza Nouraei SA, Akthar AM et al (2007) Remote ischemic preconditioning reduces myocardial and renal injury after elective abdominal aortic aneurysm repair. Circulation 116(11): I-98-I-105.
101. Kohler D, Eckle T, Faigle M, Grenz A, Mittelbronn M, Laucher S et al (2007) CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury. Circulation 116(16): 1784-1794.
102. Sugimoto S, Lin X, Lai J, Okazaki M, Das NA, Li W et al (2009) Apyrase treatment prevents ischemia-reperfusion injury in rat lung isografts. J Thorac Cardiovasc Surg 138(3): 752-759.